Anzeige
❌
Mehr »
Samstag, 10.10.2026 - Börsentäglich über 12.000 News
Elevate Sercive Group: Neue Expertise für den nächsten Wachstumsschritt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CB

WKN: A41BDZ | ISIN: KYG2545C1042 | Ticker-Symbol: C68
Frankfurt
09.10.26 | 08:07
11,800 Euro
+4,42 % +0,500
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CRESCENT BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
CRESCENT BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,60014,00009.10.

Aktuelle News zur CRESCENT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCrescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards1
DiStifel reiterates Buy on Crescent Biopharma stock, $28 target1
DiCrescent Biopharma stock rating upgraded to buy at H.C. Wainwright2
DiH.C. Wainwright stuft Crescent Biopharma auf "Kaufen" hoch3
MoCrescent Biopharma, Inc.: Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors190Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to...
► Artikel lesen
25.09.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards3
CRESCENT BIOPHARMA Aktie jetzt für 0€ handeln
18.09.CRESCENT BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans1
10.09.Crescent Biopharma auf Cantor-Konferenz: Globale Studienstrategie für Krebs-Pipeline im Fokus1
09.09.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards2
03.08.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards1
30.07.CRESCENT BIOPHARMA, INC. - 10-Q, Quarterly Report-
30.07.Crescent Biopharma, Inc.: Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights382Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001...
► Artikel lesen
30.07.CRESCENT BIOPHARMA, INC. - 8-K, Current Report1
23.07.Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards4
16.07.Crescent Biopharma, Inc.: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares194WALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
► Artikel lesen
15.07.Crescent Biopharma prices $125M public offering at $14.50/share4
15.07.Crescent Biopharma, Inc.: Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants1
14.07.Crescent Biopharma launches public offering of ordinary shares1
14.07.Crescent Biopharma startet öffentliches Aktienangebot2
14.07.Crescent Biopharma, Inc.: Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants1
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1